Skip to main content
Acta Crystallographica Section F: Structural Biology and Crystallization Communications logoLink to Acta Crystallographica Section F: Structural Biology and Crystallization Communications
. 2008 May 24;64(Pt 6):558–560. doi: 10.1107/S1744309108014681

Crystallization and preliminary X-ray analysis of vicenisaminyltransferase VinC

Eriko Nango a, Atsushi Minami a, Takashi Kumasaka b, Tadashi Eguchi c,*
PMCID: PMC2496844  PMID: 18540075

The crystallization of VinC, a glycosyltransferase involved in the biosynthesis of the antitumour antibiotic vicenistatin, is reported.

Keywords: vicenistatin, antibiotics, glycosyltransferases

Abstract

A recombinant glycosyltransferase, VinC, from Streptomyces halstedii HC34 has been crystallized at 293 K using PEG 3350 as precipitant. The diffraction pattern of the crystal extends to 2.0 Å resolution at 100 K using synchrotron radiation at SPring-8. The crystals are orthorhombic and belong to space group I222, with unit-cell parameters a = 98.21, b = 130.39, c = 140.11 Å. The presence of two molecules per asymmetric unit gives a crystal volume per protein weight (V M) of 2.43 Å3 Da−1 and a solvent content of 49.5% by volume.

1. Introduction

Vicenistatin is an antitumour β-glycosidic antibiotic produced by Streptomyces halstedii HC34. It comprises the amino sugar vicenis­amine and the 20-membered macrocycle vicenilactam (Fig. 1; Shindo et al., 1993). We have identified the gene cluster for the biosynthesis of vicenistatin and clarified that the cluster contains putative genes for vicenilactam biosynthesis; these include four modular polyketide synthases (PKSs), glutamate mutase, acyl-CoA ligase and AMP ligase (Ogasawara et al., 2004). Also found in the cluster are genes for the expression of NDP-hexose-4,6-dehydratase and aminotransferase, which are involved in vicenisamine biosynthesis.

Figure 1.

Figure 1

The transfer of vicenisamine from dTDP-α-d-vicenisamine to vicenilactam catalysed by VinC.

VinC has been identified as a vicenisaminyltransferase that catalyzes the transfer of vicenisamine from dTDP-vicenisamine to viceni­lactam in the last step of vicenistatin biosynthesis (Ogasawara et al., 2004). We recently demonstrated that VinC is able to accept structurally diverse aglycons (glycosyl acceptors) to form the respective vicenisamides (Minami, Kakinuma et al., 2005; Minami, Uchida et al., 2005). Furthermore, VinC displays glycosyltransfer activities with various dTDP-sugars, including anomers of both d- and l-sugars (Minami & Eguchi, 2007). Thus, VinC is thought to be an attractive glycosyltransferase for the generation of various glycosides because of its broad substrate specificity. In fact, previous studies have shown that new compounds could be constructed with VinC using unnatural glycosyl donors and acceptors (Minami & Eguchi, 2007). Moreover, if the structural determinants of substrate specificity can be understood, directed genetic modification of the glycosyltransferases could be exploited to yield a broader diversity of products.

In order to understand the issues underlying catalysis and substrate specificity, we have undertaken structural analysis of VinC. In this study, we report the crystallization and preliminary X-ray diffraction analysis of VinC.

2. Experimental

2.1. Crystallization

The vinC gene was cloned, inserted into the vector pET30b(+) and transformed into Escherichia coli strain BL21 (DE3) (Ogasawara et al., 2004). The expressed VinC was purified using ammonium sulfate precipitation and DEAE Sepharose Fast Flow column chromatography (Minami & Eguchi, 2007). Typical yields are 84 mg homogeneous VinC from approximately 5 g cell paste. VinC was obtained in an electrophoretically homogeneous state and its molecular weight was estimated to be 46 kDa using SDS–PAGE analysis, which was in agreement with the calculated weight of 46 066 Da. The purified enzyme was prepared in 5 mM Tris–HCl pH 8.0 and crystallization was carried out using the hanging-drop vapour-diffusion method at 293 K. A 2 µl droplet of 11 mg ml−1 protein solution mixed with the same volume of reservoir solution [20%(w/v) PEG 3350, 200 mM MgCl2 and 100 mM Tris–HCl pH 8.5] was equilibrated against 1 ml reservoir solution to obtain VinC crystals. Small needle-shaped crystals appeared in 3–6 d in this condition and grew to maximum dimensions of 0.02 × 0.02 × 0.1 mm. Microseeding was used in order to obtain larger crystals. To set up the drops for seeding, 2 µl protein solution at 11 mg ml−1 was mixed with 2 µl precipitant solution and equilibrated against the same condition as used above for 2 d. Several needle-shaped crystals were removed from their crystallization drop and transferred to a 10 µl drop of precipitant solution, where they were crushed with a spatula to generate seed crystals. The seed suspension was diluted with precipitant solution at a 1:5(v:v) ratio. Seeds were then transferred to the equilibrated drops from the seed suspension with a cryoloop (0.1–0.2 mm diameter). Crystals grew to maximum dimensions of 0.2 × 0.2 × 0.6 mm within a week of seeding.

2.2. Data collection

A drop containing the crystals (approximately 4 µl) was supplemented with 2 µl 20%(v/v) polyethylene glycol (PEG) 400 (the final concentration in the drop was approximately 11% PEG 400) because crystals broke if transferred directly to the cryosolution. After 10–­20 s, the crystals were transferred to reservoir solution supplemented with 20% PEG 400 as cryoprotectant. The crystal, mounted in a cryoloop, was flash-cooled in a liquid-nitrogen stream at 100 K. Data collection was performed at 100 K using an X-ray wavelength of 1.0 Å on BL26B1 of SPring-8 (Harima, Japan) using a Rigaku/MSC Jupiter210 detector system. Diffraction images were integrated and scaled using the programs DENZO and SCALEPACK from the HKL suite (Otwinowski & Minor, 1997).

3. Results and discussion

Preliminary screening was carried out using commercially available screening kits (Hampton Research Crystal Screens I and II and PEG/Ion Screen). The crystals obtained without seeding were small needles, but grew to maximum dimensions of 0.35 × 0.35 × 1.0 mm (Fig. 2) after seeding. The crystals diffracted X-rays to 2.0 Å resolution (Fig. 3). The space group was determined to be I222, with unit-cell parameters a = 98.21, b = 130.39, c = 140.11 Å. Assuming the presence of one dimeric subunit in the asymmetric unit, the Matthews coefficient V M (Matthews, 1968) was calculated to be 2.43 Å3 Da−1, with an estimated solvent content of 49.5%.

Figure 2.

Figure 2

Crystals of VinC. (a) Initial crystals of VinC. (b) Single crystals obtained by seeding. The average dimensions of these crystals were 0.2 × 0.2 × 0.6 mm.

Figure 3.

Figure 3

Diffraction pattern of a VinC crystal. An enlarged image of the area around 2.0 Å is shown.

Scaling and merging of the crystallographic data resulted in an overall R merge of 5.6% and an R merge in the highest resolution shell of 32.7%. Complete data-collection statistics are given in Table 1.

Table 1. Data-collection statistics.

Values in parentheses are for the highest resolution shell.

Space group I222
Unit-cell parameters (Å) a = 98.21, b = 130.39, c = 140.11
Wavelength (Å) 1.0
Resolution (Å) 100.00–2.00 (2.07–2.00)
Total observations 549280
Unique reflections 60204
I/σ(I)〉 12.9
Rmerge (%) 5.6 (32.7)
Data completeness (%) 98.5 (91.2)

R merge = Inline graphic Inline graphic, where Ii(hkl) is the ith intensity measurement of reflection hkl, including symmetry-related reflections, and 〈I(hkl)〉 is its average.

We have attempted to carry out molecular replacement for phase determination using MOLREP (Vagin & Teplyakov, 1997) with structures of homologous glycosyltransferases (PDB codes 1rrv, 1iir and 1pnv), but have not been successful. Therefore, we are preparing seleno-l-methionine-labelled VinC for structure determination.

Acknowledgments

This work was supported in part by a grant from the National Project on Protein Structural and Functional Analyses from MEXT, Japan.

References

  1. Matthews, B. W. (1968). J. Mol. Biol.33, 491–497. [DOI] [PubMed]
  2. Minami, A. & Eguchi, T. (2007). J. Am. Chem. Soc.129, 5102–5107. [DOI] [PubMed]
  3. Minami, A., Kakinuma, K. & Eguchi, T. (2005). Tetrahedron Lett.46, 6187–6190.
  4. Minami, A., Uchida, R., Eguchi, T. & Kakinuma, K. (2005). J. Am. Chem. Soc.127, 6148–6149. [DOI] [PubMed]
  5. Ogasawara, Y., Katayama, K., Minami, A., Otsuka, M., Eguchi, T. & Kakinuma, K. (2004). Chem. Biol.11, 79–86. [DOI] [PubMed]
  6. Otwinowski, Z. & Minor, W. (1997). Methods Enzymol.276, 307–326. [DOI] [PubMed]
  7. Shindo, K., Kamishohara, M., Odagawa, A., Matsuoka, M. & Kawai, H. (1993). J. Antibiot.46, 1076–1081. [DOI] [PubMed]
  8. Vagin, A. & Teplyakov, A. (1997). J. Appl. Cryst.30, 1022–1025.

Articles from Acta Crystallographica Section F: Structural Biology and Crystallization Communications are provided here courtesy of International Union of Crystallography

RESOURCES